Aflibercept biosimilar - Clover Biopharmaceuticals
Alternative Names: SCB 420Latest Information Update: 29 Apr 2022
At a glance
- Originator Clover Biopharmaceuticals
- Class Antineoplastics; Eye disorder therapies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Recombinant fusion proteins
- Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Wet age-related macular degeneration
Most Recent Events
- 19 Apr 2022 Clover Biopharmaceuticals withdraws a phase I trial in Wet-age related macular degeneration (In adults, Treatment experienced, In the elderly) in Australia, New Zealand and China (Intravitreous) (NCT04919096)
- 16 Jun 2021 Preclinical trials in Wet age-related macular degeneration in China (Intravitreous) before June 2021
- 09 Jun 2021 Aflibercept biosimilar - Clover Biopharmaceuticals is available for licensing as of 16 Jun 2021. https://www.cloverbiopharma.com/about/global-collaborations.html (Clover Biopharmaceuticals website, June 2021)